In today’s recent session, 5.89 million shares of the Reneo Pharmaceuticals Inc (NASDAQ:RPHM) have been traded, and its beta is 0.26. Most recently the company’s share price was $1.66, and it changed around -$0.15 or -8.29% from the last close, which brings the market valuation of the company to $55.48M. RPHM at last check was trading at a discount to its 52-week high of $9.45, offering almost -469.28% off that amount. The share price’s 52-week low was $0.98, which indicates that the recent value has risen by an impressive 40.96% since then. We note from Reneo Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 154.00K.
Reneo Pharmaceuticals Inc (NASDAQ:RPHM) trade information
Instantly RPHM has been showing red trend so far today with a performance of -8.29% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 3.75% year-to-date, but still down -4.05% over the last five days. On the other hand, Reneo Pharmaceuticals Inc (NASDAQ:RPHM) is -4.05% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Reneo Pharmaceuticals Inc (RPHM) estimates and forecasts
Reneo Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -74.28 percent over the past six months and at a 67.06% annual growth rate that is well above the industry average of 11.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 26.70% in revenue this quarter, and will report an increase of 69.20% in the next quarter.
